activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.  â€¢ to evaluate the impact and distribution of a single phosphodiesterase type 5 inhibitor (pde5 i) dose ( xxxd3464xxx  or tadalafil) in prostate tissue and plasma in patients with benign prostatic hyperplasia (bph).